Effectiveness of a Single Dose of Ad26.COV2.S Vaccine Against COVID-19
Author Information
Author(s): Boehme Amelia, Harvey Raymond A., Madsen Ann, Rubens Lexie, Toyip Astra, Batech Michael, Ricci Deborah, Nyaku Mawuli
Primary Institution: Aetion Inc.
Hypothesis
What is the real-world effectiveness of a single dose of Ad26.COV2.S vaccine in preventing COVID-19?
Conclusion
A single dose of Ad26.COV2.S vaccine is effective for at least 12 months in reducing the risk of COVID-19, hospitalizations, and all-cause mortality associated with COVID-19.
Supporting Evidence
- Vaccine effectiveness against any observed COVID-19 was 20%.
- Vaccine effectiveness against COVID-19-related hospitalizations was 43%.
- Vaccine effectiveness against all-cause mortality temporally associated with COVID-19 was 53%.
- Individuals vaccinated with Ad26.COV2.S had lower risks of severe COVID-19 outcomes compared to unvaccinated individuals.
- Effectiveness increased with the severity of COVID-19 outcomes.
Takeaway
Getting one shot of the Ad26.COV2.S vaccine helps protect you from getting really sick from COVID-19 for a long time.
Methodology
This was a retrospective observational study using claims data to compare outcomes between vaccinated and matched unvaccinated individuals.
Potential Biases
The study may not fully represent uninsured populations and could be biased due to reliance on insurance-based data.
Limitations
Findings may be limited by the accuracy of claims data and potential exposure misclassification.
Participant Demographics
Participants were adults aged 18 and older, with a mean age of approximately 44 years, and included a diverse range of comorbidities.
Statistical Information
P-Value
0.80 (for any observed COVID-19)
Confidence Interval
95% CI: (19, 21%) for any observed COVID-19
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website